Cantor lifts pharma price targets, but flags Pfizer growth outlook tied to Mevpro-1 results

Shares of Pfizer, Eli Lilly and Merck were in focus after Cantor issued a fresh view on the group, according to a market report carried by Yahoo Finance. The note highlighted continued interest in how each company’s pipeline and near-term execution could shape earnings expectations into the next phases of drug development.

For Pfizer, Cantor’s framing centered on Mevrometostat, an experimental prostate cancer medicine. The report said Pfizer’s near-term performance largely depends on results from the Mevpro-1 trial, implying that investors will likely look for clearer evidence of efficacy and safety as the trial advances. Mevpro-1 is the clinical study that investors will treat as a key datapoint for whether the drug can move meaningfully toward broader development and potential commercialization.

While the market report described Cantor lifting price targets across multiple large-cap pharma names, it also said the firm flagged growth concerns specific to Pfizer. The exact nature of those concerns was not detailed in the posted material beyond the suggestion that timing and trial-linked progress could be a determining factor for how the market prices Pfizer’s growth prospects.

The same update kept Lilly and Merck on the list, reflecting how analysts often tie changes in targets to anticipated pipeline milestones, competitive positioning, and the cadence of clinical readouts. However, the material available for this story did not provide specific trial names, drug programs, or numeric target changes for Lilly or Merck.

The broader takeaway for healthcare markets is that large pharma’s stock moves frequently track not only current sales but also the next set of binary clinical events that can reset expectations for growth. When an analyst highlights one trial as a near-term driver, it can concentrate investor attention on the timing of future data, the endpoints a study uses, and how results may compare with available standard-of-care therapies.

Still, important details were not disclosed in the market report that is available here. The posting does not include the size of Cantor’s price-target changes, the underlying assumptions behind the growth concerns, or any direct quotes from the firm. It also does not specify what stage Mevpro-1 is in, which endpoints are expected, or when investors might realistically get additional readouts.

What to watch next is how Pfizer communicates with investors around Mevpro-1 progress and any additional information that could reduce uncertainty about Mevrometostat’s prospects. For the other drugmakers mentioned alongside Pfizer, the next stock catalysts are likely to remain centered on pipeline updates and analyst estimates for how new treatments could contribute to earnings over time.